The present invention relates to the use of a control marker for implementing analysis methods on spots, in particular in the context of multiplex analyses. The present invention thus relates to solid supports containing said control marker, their preparation method and their use in analysis methods. The present invention makes it possible to verify the presence, location and/or integrity of the spots at the end of the analysis method, and thus to secure the obtained results while guaranteeing that the yielded result indeed results from a present, intact and localized spot.

Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide-alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.

Provided is a method of using an aptamer for detecting a glycated hemoglobin in a whole blood, the method includes that the aptamer is provided, the aptamer includes a DNA sequence selected from the group consisting of derived sequences of SEQ ID NOs: 1, 2, 3, and 4, in which the derived sequences refer to that 3′ end and/or 5′ end of the derived sequences are modified, and the derived sequences have 90% identity to the SEQ ID NOs: 1, 2, 3, and 4. The aptamer and the whole blood are contacted. A concentration of a conjugate of the aptamer and the glycated hemoglobin is estimated. Provided also is a nanoelectronic aptasensor including the above aptamer.

The invention is directed to a conjugate having the general formula (I)

##STR00001## Wherein AR and MU are repeating units of a polymer MU is a polymer modifying unit or band gap modifying unit that is evenly or randomly distributed along the polymer main chain, G1 and G2 stand for hydrogen, halogen or an antigen recognizing moiety, with the provision that at least one of G1 or G2 is an antigen recognizing moiety, a is 10 to 100 mol %, b is 0 to 90 mol % c is 1 to 10 000; with the provisio that a+b=100 mol % characterized in that AR is connected in the polymer chain via the 2,2′ or 3,3′ or 5,5′ or 6,6′ or 7,7′ or 8,8′ positions according to general formula (II)

##STR00002## Wherein the remaining positions 2,2′; 3,3′; 4,4′; 5,5′; 6,6′; 7,7′ and 8,8′ are substituted with same or different residues selected from the group consisting of H, SO.sub.2CF.sub.3, SO.sub.2R.sub.a, CF.sub.3, CCl.sub.3, CN, SO.sub.3H, NO.sub.2, NR.sub.aR.sub.bR.sub.c.sup.+, CHO, CORa, CO.sub.2Ra, COCl, CONRaRb, F, Cl, Br, I, R.sub.a, OR.sub.a, SR.sub.a, OCOR.sub.a, NR.sub.aR.sub.b, NHCOR.sub.a, CCR.sub.a, aryl-, heteroaryl-, C.sub.6H.sub.4OR.sub.a or C.sub.6H.sub.4NRaRb, with Ra-c independently hydrogen, alkyl-, alkenyl-, alkinyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or a heteroaralkyl residue or (CH.sub.2)x(OCH.sub.2CH.sub.2)yO(CH.sub.2)zCH.sub.3, wherein x is an integer from 0 to 20; y is an integer from 0 to 50 and z is an integer from 0 to 20

The invention is directed to a conjugate having the general formula (I)

##STR00001## Wherein AR, MU and MU* are repeating units of a polymer and MU and MU* are polymer modifying units or band gap modifying units which are evenly or randomly distributed along the polymer main chain, G1 and G2 stand for hydrogen, halogen or an antigen recognizing moiety, with the provision that at least one of G1 or G2 is an antigen recognizing moiety, a is 10 to 100 mol %, b is 0 to 90 mol % c is 0.1 to 90 mol % d is 1 to 10 000; with the provisio that a+b+c=100 mol % characterized in that AR is connected in the polymer chain via the 2,2′ or 3,3′ or 4,4′ or 5,5′ or 6,6′ or 7,7′ or 8,8′ positions according to general formula (II)

##STR00002## Wherein the remaining positions 2,2′; 3,3′; 4,4′; 5,5′; 6,6′; 7,7′ and 8,8′ are substituted with same or different residues selected from the group consisting of H, SO.sub.2CF.sub.3, SO.sub.2R.sub.a, CF.sub.3, CCl.sub.3, CN, SO.sub.3H, NO.sub.2, NR.sub.aR.sub.bR.sub.c.sup.+, CHO, CORa, CO.sub.2Ra, COCl, CONRaRb, F, Cl, Br, I, R.sub.a, OR.sub.a, SR.sub.a, OCOR.sub.a, NR.sub.aR.sub.b, NHCOR.sub.a, CCR.sub.a, aryl-, heteroaryl-, C.sub.6H.sub.4OR.sub.a or C.sub.6H.sub.4NRaRb, with Ra-c independently hydrogen, alkyl-, alkenyl-, alkinyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or a heteroaralkyl residue or (CH.sub.2).sub.x(OCH.sub.2CH.sub.2).sub.yO(CH.sub.2).sub.zCH.sub.3, wherein x is an integer from 0 to 20; y is an integer from 0 to 50 and z is an integer from 0 to 20.

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention further provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting anti-repeat-associated non-ATG (RAN) protein antibodies in a subject (e.g., a subject that has been administered a therapeutic anti-RAN protein antibody or a vaccine against a disease or disorder associated with RAN protein expression, translation, and/or accumulation, for example amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD)). In some embodiments, methods described by the disclosure comprise detecting one or more anti-RAN protein antibodies in a biological sample obtained from a subject by an electrochemiluminescence-based immunoassay using one or more target di-amino acid repeat peptides. In some embodiments, the disclosure relates to kits comprising one or more di-amino acid repeat peptides and an electrochemiluminescence-based immunoassay plate and/or reagents.

The present disclosure discloses a microfluidic structure, a microfluidic chip and a detection method. The microfluidic structure includes: a first base substrate and a second base substrate opposite to each other, an antibody area located between the first base substrate and the second base substrate and storing an enzyme-labeled first antibody, a cleaning area storing cleaning liquid, a signal substrate area storing a signal substrate solution and a detection area with a second antibody and an ion sensitive film fixed thereon, wherein all channel areas from the antibody area, the cleaning area and the signal substrate area to the detection area each have a driving electrode structure driving liquid drops to move; and the detection area has a thin film transistor connected with the ion sensitive film.

A method for detecting a plurality of target substances using a plurality of conjugates each including a binding substance and a label is provided. The binding substance has an activity to bind to one of the target substances and the label causes a detectable phenomenon. The method includes binding at least some of the plurality of conjugates with the plurality of target substances, removing a remainder of the plurality of conjugates that is not bound to the plurality of target substances, and detecting the label. A molecular weight of the binding substance is less than a molecular weight of an immunoglobulin.

The invention relates to the field of biomedical and pharmacological research, in particular in the field of immunology, allergies, cancers, bone diseases and autoimmune diseases. The invention is based on the recent finding that SWAP-70 dimerizes, that the dimerization takes place via a specific, largely unique and limited region of the protein, and that this dimerization is central to the function of the protein (and probably the stability thereof). The invention provides a screening method which makes it possible to identify new active ingredients which, by accumulating at the dimerization domain and inhibiting SWAP-70 activity, suppress the supporting function of SWAP-70 in tumorigenesis, tumor cell migration and invasion, bone-degrading osteoclast activity, and the allergic reaction, as well as in autoimmune diseases. The object is achieved by a method for identifying a substance which inhibits the activity of SWAP-70, wherein the method comprises the following: contacting at least one test substance with SWAP-70, detecting the degree of dimerization of SWAP-70, selecting a test substance which inhibits the dimerization of SWAP-70.